ArriVent reports H1 results and licenses ARR-002 to Allist for up to $80.6M

ArriVent BioPharma, Inc.

Entered exclusive license with Allist for ARR-002 in Greater China; potential $80.6M in upfront, milestones, plus tiered royalties (mid-single to low-double digit).
Cash and investments $373.1M at June 30, 2026; expected to fund operations into 2028.
Net loss $93.2M for H1 2026 vs $95.8M in H1 2025; R&D $80.0M, G&A $18.8M.
Firmonertinib Phase 3 FURVENT topline data for EGFR exon20 NSCLC expected 2H 2026.
ARR-002 first patient dosing expected Q3 2026; ARR-217 advanced to Phase 1b dose optimization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.